Norges Bank Amylyx Pharmaceuticals, Inc. Transaction History

Norges Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$12.07 - $18.46 $1.4 Million - $2.15 Million	116,400 New	116,400 $1.71 Million
Q2 2023 Aug 14, 2024	BUY	$20.98 - $31.42 $1.76 Million - $2.64 Million	84,100 New	84,100 $1.81 Million
Q1 2023 May 15, 2024	BUY	$27.71 - $40.93 $2.55 Million - $3.76 Million	91,900 New	91,900 $2.7 Million
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $2.42 Million - $3.19 Million	81,200 New	81,200 $3 Million

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $308M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.